You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
CLL: Was Bruton-Kinase-Inhibitoren der 2. Generation leisten können
Contributor:
Welslau, Manfred
Published:
S. Karger AG, 2021
Published in:
Kompass Onkologie, 8 (2021) 2, Seite 75-76
Language:
English
DOI:
10.1159/000516872
ISSN:
2296-5386;
2296-5416
Origination:
Footnote:
Description:
Treatment standards for chronic lymphocytic leukemia (CLL) have been transformed with the advent of effective inhibitors of B-cell receptor signaling such as ibrutinib – a first-in-class inhibitor of BTK. Off-target kinase inhibitions by ibrutinib are thought to contribute to its adverse events. Zanubrutinib is a next-generation BTK inhibitor with minimal off-target effects, sustained BTK occupancy in peripheral blood mononuclear cells and lymph nodes from patients with B-cell malignancies and promising responses in patients with CLL. Described here is a head-to-head Phase III study comparing the efficacy and safety of zanubrutinib with those of ibrutinib in patients with CLL/small lymphocytic lymphoma in the relapsed/refractory setting.